In the present study, we evaluated GCK expression by measuring the average immunoreactivity of GCK in insulin+ or glucagon+ cells from pancreatic sections of nondiabetic (ND), impaired fasting glucose (IFG), and T2D patients with different glycemic control. The gene discussed is GCG; the disease is type 2 diabetes mellitus.